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Abstract: Time-dependent distribution of selegiline was monitored in various tissues of rabbits 
treated with a dose of 30 mg/kg intravenously. Selegiline content was determined by validated RP-
HPLC method following 5,15, 30, 60 and 120 minutes of treatment. The present study confirming earlier data showed that 
selegiline readily penetrates through the blood brain barrier, however, as a new result, high selegiline concentrations were 
measured in the lacrimal glands, lungs and testes as well as in the eyes of rabbits at each time point studied. When se-
legiline concentrations in the different eye segments were determined, a time-dependent decline of selegiline tissue levels 
was observed in the iris, the cornea and the intraocular lens, while the maximum level of selegiline in the retina found at 
15 min and even at 60 min, was similar to that determined at 5 min following administration. 
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INTRODUCTION 
Selegiline is one of the most widely used monoamine 
oxidase B inhibitors. Its human indications include Parkin-
son’s disease [1, 2], and depression and its advantages were 
suggested in the study of the pathomechanism of Alz-
heimer’s disease [3]. Its beneficial effects in Parkinson’s 
disease were well established by its selective and irreversible 
inhibition of MAO-B enzyme in the brain [4], and also by its 
inhibitory effect on high affinity dopamine reuptake [5-7] as 
well as its dopamine releasing effects following chronic 
treatment [8]. 
Lifespan was prolonged [9-12], the cognitive function 
[13] and sexual activity of rats were definitely improved by 
chronic treatments of selegiline, which were reported in a 
number of in vivo studies [14-16]. Nowadays, these effects 
are summarized as senolytic [17]. According to Kitani et al 
[9] the lifespan-prolongating effect of selegiline can be 
explained by its upregulating effect in the dopaminergic 
brain areas of several animal species (mice, rats, hamsters 
and dogs) on the activity of anti-oxidant enzymes such as 
catalase (CAT) and superoxide dismutase (SOD). This 
upregulation of CAT and SOD was also found in several 
extra-cranial organs (the adrenal glands, heart, kidney and 
spleen) and mobilization of humoral factors (interferone-γ, 
tumor necrosis factor, etc.) was also observed by Kitani et al 
[9]. At the same time, no explanation for the increase in 
sexual activity was provided [14-16]. However, selegiline's  
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oral bioavailability was found drastically (10- to 20-fold) 
increased in females taking oral contraceptives [18].  
Selegiline is a lipophilic compound with a positive logP 
value [19, 20]. Its metabolism [21] yields three major me-
tabolites, such as desmethylated selegiline ((-)-nordeprenyl, 
which keeps the MAO-B inhibitory effect of selegiline), de-
spropargyl selegiline ((-)-methamphetamine) and desmethyl-
despropargyl selegiline, which is the (-)-amphetamine me-
tabolite. The metabolism of selegiline is essentially carried 
out by cytochrome P 450 (CYP) enzymes [22-24]. Benetton 
et al. [25] used recombinant human CYP enzymes to identify 
which ones are mainly involved in the metabolism of se-
legiline, thereby taking part in the removal of selegiline from 
the body. Their experimental results show that the major 
enzymes in selegiline→metamphetamine conversion are 
CYP 2C19, CYP 3A4 and CYP1A2. Kamada et al [24] also 
attributed an important role to CYP2D6 in the metabolism of 
selegiline. Tóth-Molnár et al. [26] determined selegiline me-
tabolites in the rabbits’ blood, livers, kidneys and eyes. 
To avoid the first-pass effect of selegiline, buccal films 
were impregnated with selegiline nanospheres and the com-
parative pharmacokinetics profile of the buccal film with oral 
solution was studied in rabbits [27]. Orally disintegrating se-
legiline tablets [28] can also be used for the same reason.  
Pharmacokinetics (PK) of selegiline (Jumex®) in rats, 
beagle dogs, mini-pigs has been published, in addition to that 
of humans. However, pharmacokinetics of selegiline (with-
out any advanced formulation) has not yet been published on 
rabbits. The rabbit model can be preferred when the distribu-
tion of selegiline (Jumex®) levels in the different eye seg-
ments (the iris, cornea, retina, lens) should be determined 
and compared.  
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Only few publications detail the effect of selegiline on 
eyes [29]. Recently high selegiline levels were published on 
the rat eyes [30]. The distribution of selegiline in the eye 
segments has not been studied. The presence of MAO-B 
activity in bovine eyes was detected [31], in the retina, the 
optic nerve, the iris and the epithelium. However in the rab-
bit retina the MAO-A isoform was shown to be dominant 
[32].  
Xu et al. [33] studied the effect of selegiline in cultured 
retinal neurons, and found dose-dependent blocking of apop-
tosis in the concentration range from 0.001 through 10 µM. 
This paper introduces the pharmacokinetics of selegiline 
in rabbit tissues, including its time-dependent distribution in 
the serum, the brain, the cerebrospinal fluid, the testis, the 
liver, the lungs, the lacrimal glands and in eye segments (the 
cornea, iris, lens and retina). 
EXPERIMENTAL 
Treatment of animals: Male white New Zealand rabbits 
weighing 2.0±0.2 kg, were purchased from Dévai Farm 
(Kondoros, Hungary). Selegiline (L-deprenyl, Fig. 1), 
freshly dissolved in saline, was intravenously (i.v.) adminis-
tered through the ear vein. The protocol was approved by the 
Ethical Committee for Protection of Animals in Research in 
the Department of Pharmacology, University of Szeged 
(XIII:/1211/2012), being in accordance with the Directive 
2010/63/EU of the European Parliament.  
Hardware of HPLC: The chromatographic analyses 
were performed using a JASCO system (Tokyo, Japan sup-
plied by the local distributor ABL&E Jasco Kft, Budapest) 
equipped with a DG-2080-54 Degasser, PU-1580 Pump, AS-
2057 Plus Autosampler (temperature kept at 4 °C) and with 
an Antec Leyden Decade Amperometric Detector at Eox: 
0.9 V, (Zoeterwoude, the Netherlands) and a UV-975 
UV/Vis Detector (operated at 265 nm). All chromatograms 
were stored and evaluated using a Borwin 1.50 Chromatog-
raphy software (JMBS, Le Fontanil, France). The stationary 
phase of separation was a Zorbax Rx-C18 octadecyl silica 
column (4.6 mm × 250 mm, 5 µm) (Agilent Technologies, 
supplied by the local distributor Kromat Kft., Budapest, 
Hungary). The mobile phase was a phosphate/citric acid 
buffer (pH 3.7) containing sodium 1-decanesulfonate and 
acetonitrile. The flow rate of the mobile phase was 1 ml/min, 
the column was kept at 35 °C and the injection volume was 
75 µl. Conditions of sample treatments and validation of 
HPLC determinations are detailed in our recent publications 
[30, 34]. HPLC of rabbit iris samples is given in Fig. (2). 
RESULTS 
Samples from the serum, brains, CSF, lungs, lacrimal 
glands, testes and eye segments of selegiline-treated rabbits 
showed excellent and time-dependent distribution of the 
compound in the tissues studied. The time-dependent levels 
of selegiline in various organs and body fluids of rabbits 
injected with a 30 mg/kg intravenous dose following 5, 15, 
30, 60 and 120 minutes are shown in Table 1. The selegiline 
concentrations in the brains were higher than in the serum at 
all points of time studied except at 120 min. In the cerebro-
spinal fluid selegiline concentrations were only about half of 
that in the serum. In the livers, selegiline concentrations 





Fig. (1). The chemical structure of selegiline (L-deprenyl). 
 
Fig. (2). HPLC of rabbit iris samples using an Amperometric Detector at Eox: 0.9 V. (A: blank iris, B: spiked iris, C: iris sample from treated 
rabbit). The peak of selegiline is at 9 min.  
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Interestingly, in the lacrimal glands the selegiline con-
centrations showed very high levels, with the highest value 
following 30 minutes after administration, when it was 
twenty eight-fold higher than that in the serum. This high 
concentration remained even at the end of the observation 
period (two hours after selegiline administration). Selegiline 
tissue levels in the testes were also strikingly very high with 
a maximum at 15 min and even at 60 min they were much 
higher than in the serum. Among the eye segments, se-
legiline concentrations at 5 min, the iris showed the highest 
tissue concentration with continuous decline, while in the 
retina the maximum was observed at 15 min followed by a 
decline producing similar levels in the serum in the first hour 
following administration. When the tissue concentration ra-
tios in the retina were compared to the other eye compart-
ments, the following ranking could be seen at 5 min: iris > 
cornea > retina, while at each other time point the ranking 
was: retina>> iris > cornea. At the same time the selegiline 
concentrations in the lacrimal glands were almost a magni-
tude of order higher than in any of the eye segments.  
DISCUSSION 
There are two possibilities for the termination of the ef-
fect of xenobiotics administered to living organisms (1) non-
physical cessation by their metabolism, that mainly happens 
in the liver by dealkylations; (2) physical removal of the par-
ent compound and/or its metabolites mainly done by the kid-
ney, bile, perspiratory gland, salivary gland and lacrimal 
gland as well as by expiration through the lungs. In the case 
of selegiline both the parent compound and its metabolites 
are effectively removed [35]. 
Pharmacokinetics of selegiline has not yet been published 
in rabbits. Using a validated RP-HPLC method [30, 35] as a 
new result, in our present study, we have demonstrated strik-
ingly high selegiline tissue levels in the lacrimal glands and 
testes as well as in the eye segments of rabbits. The se-
legiline level in the lacrimal glands of rabbits showed up-
most high concentrations at 30 minutes following admini-
stration. It is suggested, that selegiline’s MAO inhibitory 
effect in the lacrimal gland results in elevated dopamine 
level, which was reported to stimulate ion transport in the 
corneal epithelium [36].  
The anti-parkinsonian effect of selegiline is mainly based 
on the selective inhibition of monoamine oxidase B enzyme 
in the brain [2]. It is evident that selegiline can also show 
similar selective and irreversible inhibition of monoamine 
oxidase B enzyme in any other organs of the body wherever 
it is present. Inhibition of MAO activity can lead to de-
creased inactivation of endogenous MAO substrates (dopa-
mine, phenylethylamine, serotonin etc.).Inhibited MAO ac-
tivity may be one of the factors contributing selegiline’s de-
creasing effect in cognitive and/or sexual decline during age-
ing of rats [37], so selegiline can be considered a senolytic 
drug. 
Only a few reports have been dealing with the MAO ac-
tivity in the rabbit eye [38]. Ocular hypotensive effect [39] 
was found in rabbits following topical administration of 
clorgyline , the selective and irreversible MAO-A inhibitor. 
Single administration of clorgyline caused a clinically sig-
nificant decrease in the intraocular pressure, however, treat-
ment with selegiline was practically ineffective in patients 
with glaucoma. Mallampali et al. [40] found nonreactive 
pupils as a consequence of overdose of MAO inhibitors. 
Bausher [41] reported detection and identification of both 
MAO-A and MAO-B in iris-ciliary body of albino rabbits. 
Zeller et al. [42] differentiated the effect of topical use of 
inhibitors of MAO-A and MAO-B on the rabbit iris. When a 
monoamine-releasing compound (Ro-1284) was given to the 
majority of its effects was prevented by selegiline [42]. 
Selegiline definitively protected the retina from the dam-
age caused by the intravitreal injection of NMDA [43]. Se-
legiline protection meant that neither a decrease in the den-
sity of the ganglion cells nor in the thickness of the inner 
plexiform layer could be observed. Ragaiey et al. [32] re-
ported that selegiline (0.01 through 100 µM) dose-
dependently increased the survival rate of immortalized rat 
retinal precursor cells and prevented injured retinal precursor 
cells from apoptosis. At the same time, selegiline failed to 
promote significant axonal regeneration of rat ganglion cells 
of the retina [44].  
Buys et al. [45] concluded that after an experimental 
crash of optic nerve, selegiline could significantly facilitate 
the survival of ganglion cells of the rat retina.  
We have also demonstrated very high selegiline levels in 
the testes during the whole experimental period. The same 
phenomenon was found in rats [30]. The peak concentrations 
of selegiline in the testes are comparable to those measured 
in the serum, but the selegiline concentrations in the testes 
show slower decline than in the serum. The distribution of 
selegiline in the testes and possibly in the seminal plasma 
and an increased copulation ability of rats, and also that of 
humans may be coincidental. The elevated concentration of 
monoamine oxidase in human seminal plasma was found to 
be a parallel phenomenon with infertility [46]. Mihalik et al. 
[47] recently published experimental proofs that deprenyl 
highly improves reproductive capacity of male rats. 
Based on reports on the MAO inhibitor pargyline and 
clorgyline - their inhibitory effect on testicular MAO activity 
- it is strongly suggested that selegiline has also the ability to 
inhibit MAO in the testes and in the seminal plasma.  
CONCLUSION 
Fine and precise dissection of eye compartments was 
made possible when rabbits were used as model subjects of 
our experiments. Differentiation by the dissection of various 
eye compartments (such as the retina, cornea, iris, lacrimal 
gland and intraocular lens) is of basic importance, as the 
retina belongs to the central nervous system. This fact is also 
mirrored by pharmacokinetic data as a delayed maximum 
level in the retina compared to cornea and iris. The ex-
tremely high selegiline level in the lacrimal gland and its 
definitely late tissue level maximum require further physio-
logical and pharmacological investigations. 
Selegiline is distributed in all body compartments that 
contain monoamine oxidase B enzyme. Our new experimen-
tal findings on high selegiline tissue levels in the testis, lac-
rimal gland and other eye segments open the question, how 
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physiological functioning of these organs are influenced by 
therapeutic administration of selegiline. 
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